Author Archives: admin


Allogeneic Stem Cells Market Expected to Grow with a CAGR of 12% Due to New Product Approvals, 2020-2024 – ResearchAndMarkets.com – Business Wire

DUBLIN--(BUSINESS WIRE)--The "Allogeneic Stem Cells Market by Application and Geography - Forecast and Analysis 2020-2024" report has been added to ResearchAndMarkets.com's offering.

Global Allogeneic Stem Cells Market: About this market

The allogeneic stem cells market analysis considers sales from regenerative therapy and drug discovery and development applications. Our study also finds the sales of allogeneic stem cells in Asia, Europe, North America, and ROW. In 2019, the regenerative therapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as functional restoration of tissues will play a significant role in the regenerative therapy segment to maintain its market position. Also, our global allogeneic stem cells market report looks at factors such as new product approvals, increasing strategic alliances in the field of regenerative medicines, and investments in the field of regenerative medicines. However, stringent regulations, high cost of allogeneic stem cell therapies, and serious complications associated with stem cell therapies may hamper the growth of the allogeneic stem cell industry over the forecast period.

Global Allogeneic Stem Cells Market: Overview

New product approvals

The new product approvals and special drug designations are anticipated to boost the growth of the market. Based on the application, the allogeneic stem cells market has been segmented into regenerative therapy and drug discovery and development. Manufacturers are increasingly emphasizing innovations and improvisation in the development of regenerative therapies. Many of the regenerative therapeutic candidates have obtained approval for clinical trials in the US, Europe, and APAC due to the efficacy of allogeneic stem cell therapeutics. This is encouraging market players to launch new product lines to stimulate the overall product demand for stem or regenerative therapy using allogeneic stem cell therapeutics and provide better options for their customers. Thus, new product approvals will lead to the expansion of the global allogeneic stem cells market at a CAGR of over 12% during the forecast period.

Special drug designations

Research in the field of stem cell focuses mainly on developing new treatments for deadly diseases, which have negligible treatment using traditional treatment options. Thus, therapeutic candidates, which are currently under development, have been awarded special drug designations by regulatory bodies considering their proven efficacy. Many drugs received designations such as the breakthrough drug designation and the orphan drug designation from regulatory bodies such as the US FDA and the EMA. Drug designations enhance the research and enable drugs to reach the market and provides strong incentives, which in turn, encourages vendors to expedite R&D on novel therapies such as allogeneic stem cell therapy. This development is expected to have a positive impact on the overall market growth.

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

PART 04: MARKET SIZING

PART 05: FIVE FORCES ANALYSIS

PART 06: MARKET SEGMENTATION BY APPLICATION

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

PART 13: VENDOR ANALYSIS

For more information about this report visit https://www.researchandmarkets.com/r/phsh0a

View post:
Allogeneic Stem Cells Market Expected to Grow with a CAGR of 12% Due to New Product Approvals, 2020-2024 - ResearchAndMarkets.com - Business Wire

Global Stem Cell Market Is Projected to Grow at a CAGR of 11.9% During the Forecast Period – Press Release – Digital Journal

A recent report published by Infinium Global Research on stem cell market provides an in-depth analysis of segments and sub-segments in the global as well as regional stem cell market

This press release was orginally distributed by SBWire

Pune, India -- (SBWIRE) -- 01/13/2020 -- Infinium Global Research has recently published a trending report on the Global Stem Cell Market (Type - Adult Stem Cell, Induced Pluripotent Stem Cell, Human Embryonic Stem Cell, and Other Types; Application - Regenerative Medicine, Neurology, Oncology, Cardiology, and Other Application; End User - Therapeutics Companies, Cell and Tissue Banks, Tools and Reagents Companies, and Service Companies): Global Industry Analysis, Trends, Size, Share and Forecasts to 2025. A stem cell has a unique ability to develop into specialized cell types in the body depending on the source of stem cells and their biological plasticity. Owing to their ability to transform into the new cell, they can be used to replace cells and tissues that have been damaged or lost due to disease. Stem cell therapy is a unique technique that can be used in tissue regeneration, cardiovascular disease treatment, brain disease treatment, and blood cell regeneration treatment. According to the report, the global stem cell market is projected to grow at a CAGR of 11.9% over the forecast period of 2019-2025.

For More Details Get FREE Sample Pages of this Premium Global Report@ https://www.infiniumglobalresearch.com/reports/sample-request/13006

Research Projects are Set to Offer New Opportunities for the Growth of the Stem Cell Market

A multi-disciplinary research team, based at the Wellcome-MRC Cambridge Stem Cell Institute (University of Cambridge), studied young and old rat brains to understand the impact of age-related brain stiffening on the function of oligodendrocyte progenitor cells (OPCs).

"MS is relentless, painful, and disabling, and treatments that can slow and prevent the accumulation of disability over time are desperately needed. The Cambridge team's discoveries on how brain stem cells age and how this process might be reversed have important implications for future treatment because it gives us a new target to address issues associated with aging and MS, including how to potentially regain lost function in the brain."- Dr. Susan Kohlhaas, Director of research at the MS Society

Adult Stem Cell Segment is Expected to Maintain its Dominance Over the Forecast Period

According to the analyst at Infinium Global Research, the scope of the market is analyzed on the basis of type, application, and end-user. Based on the type the study includes adult stem cells, induced pluripotent stem cell, human embryonic stem cell, and other types. Based on the application, the study includes regenerative medicine, neurology, oncology, cardiology, and other application. Based on the end-user, the study includes therapeutics companies, cell and tissue banks, tools and reagents companies, and service companies.

Based on the type of adult stem cell segment is expected to dominate the market due to factors such as minimal ethical issues, lower rejection rates, and long-term renewal property associated with stem cell utility has contributed to the dominance of this segment.

Ask Discount for the Latest Research Report @ https://www.infiniumglobalresearch.com/reports/request-discount/13006

Regional Analysis

North America Dominates the Stem Cell Market and Anticipated to Stay on Top During the Forecast Period

Advanced healthcare facilities and increasing funding for research and development are and well-established reimbursement policies and the presence of major market players are supporting the growth of the market in this region.FDA published four guidance documents in November 2017 that supplement existing statutes and together form its regenerative medicine regulatory framework. With these guidance documents, the FDA sought to clarify the distinctions between products that are subject to full drug approval requirements and those that are not.

Competitive Analysis

The key players profiled in the report are Cellular Engineering Technologies Inc., Advanced Cell Technology, Inc., STEMCELL Technologies Inc., BIOTIME, Inc., Astellas Pharma Inc., BrainStorm Cell Therapeutics, Celgene Corporation, CellGenix GmbH, Genea BioCells, Lonza Group AG, and Other companies.

In 2019, STEMCELL Technologies Win Deloitte Best Managed Companies' Award

STEMCELL Technologies is Canada's largest biotechnology company that develops specialized cell culture media, cell isolation systems, accessory products and scientific services that are used by life sciences researchers working in cell therapy, cancer research, and regenerative medicine fields.

In November 2019,BrainStorm Cell Therapeutics Inc.announced the publication of "NurOwn Phase 2 Randomized Clinical Trial in ALS: Safety, Clinical and BioMarker Results," in the international, peer-reviewed journalNeurology.

Browse Complete Global Report and Detailed TOC: https://www.infiniumglobalresearch.com/healthcare-medical-devices/global-stem-cell-market

About usThe Infinium Global research comprises of a team of well-experienced analysts who have qualified in generating incisive reports. The stem cell report offers trends, opportunities, challenges, market size, and forecast for major geographical regions and key countries. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of the stem cell market.

For more information on this press release visit: http://www.sbwire.com/press-releases/global-stem-cell-market-is-projected-to-grow-at-a-cagr-of-119-during-the-forecast-period-1270550.htm

Read the original post:
Global Stem Cell Market Is Projected to Grow at a CAGR of 11.9% During the Forecast Period - Press Release - Digital Journal

Stemline Therapeutics Announces Preliminary 2019 Net Revenues for ELZONRIS (tagraxofusp) and Highlights Commercial and Clinical Growth Drivers -…

NEW YORK, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced preliminary net revenues for 2019, as well as outlined key BPDCN market successes and upcoming commercial and clinical milestones.

Unaudited preliminary 2019 results include:

The above financial information is based on preliminary unaudited information, is subject to adjustment, and does not present all information necessary for an understanding of the Companys full-year and fourth quarter financial results for 2019. Stemline expects to report complete audited 2019 financial results on or before March 16, 2020.

Robert Francomano, Chief Commercial Officer of Stemline, stated, We are very pleased with the solid uptake seen in the first year of the ELZONRIS launch, as we continue to successfully create, penetrate and grow a new market in BPDCN. Given the orphan nature and unique features of this disease, we believe patient starts were subject to significant quarterly variance a phenomena that will likely continue throughout 2020. We are actively implementing a host of tactics to expand and further penetrate this emerging market.

Ivan Bergstein, CEO of Stemline, commented, 2019 was a transformational year for Stemline as we launched ELZONRIS, the first and only CD123 targeted agent and first agent ever approved for patients with BPDCN. We continue to pursue growth opportunities not only in BPDCN but also in a number of malignancies where targeting CD123 could provide therapeutic benefit. We look forward to data readouts in CMML, MF, and AML, including in patient subsets with high CD123, later this year and on into next year. Given our continued commercial and clinical progress, we look forward to a productive 2020 and beyond.

Corporate Highlights and Key Commercial and Clinical Milestones

BPDCN

Chronic Myelomonocytic Leukemia (CMML)

Myelofibrosis (MF)

Acute Myeloid Leukemia (AML)

About ELZONRISELZONRIS(tagraxofusp), a CD123-directed cytotoxin, is approved by the U.S. Food and Drug Administration (FDA) and commercially available in the U.S. for the treatment of adult and pediatric patients, two years or older, with blastic plasmacytoid dendritic cell neoplasm (BPDCN). For full prescribing information in the U.S., visit http://www.ELZONRIS.com. In Europe, a marketing authorization application (MAA) is under review by the European Medicines Agency (EMA). ELZONRIS is also being evaluated in additional clinical trials in other indications including chronic myelomonocytic leukemia (CMML), myelofibrosis (MF), and acute myeloid leukemia (AML).

About BPDCN BPDCN is an aggressive hematologic malignancy with historically poor outcomes and an area of unmet medical need. BPDCN typically presents in the bone marrow and/or skin and may also involve lymph nodes and viscera. The BPDCN cell of origin is the plasmacytoid dendritic cell (pDC) precursor. The diagnosis of BPDCN is based on the immunophenotypic diagnostic triad of CD123, CD4, and CD56, as well as other markers. For more information, please visit the BPDCN disease awareness website at http://www.bpdcninfo.com.

About CD123CD123 is a cell surface target expressed on a wide range of myeloid tumors including blastic plasmacytoid dendritic cell neoplasm (BPDCN), certain myeloproliferative neoplasms (MPNs) including chronic myelomonocytic leukemia (CMML) and myelofibrosis (MF), acute myeloid leukemia (AML) (and potentially enriched in certain AML subsets), myelodysplastic syndrome (MDS), and chronic myeloid leukemia (CML). CD123 has also been reported on certain lymphoid malignancies including multiple myeloma (MM), acute lymphoid leukemia (ALL), hairy cell leukemia (HCL), Hodgkins lymphoma (HL), and certain Non-Hodgkins lymphomas (NHL). In addition, CD123 has been detected on some solid tumors as well as autoimmune disorders including cutaneous lupus and scleroderma.

About Stemline Therapeutics Stemline Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. ELZONRIS(tagraxofusp), a targeted therapy directed to CD123, is FDA-approved and commercially available in the U.S. for the treatment of adult and pediatric patients, two years and older, with blastic plasmacytoid dendritic cell neoplasm (BPDCN). In Europe, a marketing authorization application (MAA) is under review by the European Medicines Agency (EMA). ELZONRIS is also being evaluated in clinical trials in additional indications including chronic myelomonocytic leukemia (CMML), myelofibrosis (MF) and acute myeloid leukemia (AML). Additional pipeline candidates include: felezonexor (SL-801) (XPO1 inhibitor; Phase 1 in advanced solid tumor patients ongoing), SL-1001 (novel RET kinase inhibitor, IND-enabling studies ongoing), SL-701 (immunotherapeutic; Phase 2 in glioblastoma patients completed), and SL-901 (novel kinase inhibitor; prior abbreviated European Phase 1, IND-enabling studies ongoing). For more information, please visit the companys website at http://www.stemline.com.

Forward-Looking StatementsSome of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The factors that could cause our actual results to differ materially include: the risk that our actual revenue for the fourth quarter and year endedDecember 31, 2019may differ materially from our estimated results for these periods as a result of the completion of year-end closing procedures or the audit of our financial statements; the success of our U.S. launch and commercialization; the success of our MAA submission to the EMA and potential launch in Europe; the success and timing of our clinical trials and preclinical studies for our product and product candidates, including ELZONRIS in additional indications and our other pipeline candidates, including site initiation, institutional review board approval, scientific review committee approval, patient accrual, safety, tolerability and efficacy data observed, and input from regulatory authorities including the risk that the FDA, EMA, or other ex-U.S. national drug authority ultimately does not agree with our data, find our data supportive of approval, or approve any of our product candidates; the possibility that results of clinical trials are not predictive of safety and efficacy results of our product candidates in broader patient populations or of our products if approved; our plans to develop and commercialize our product candidates, including, but not limited to delays in arranging satisfactory manufacturing capabilities and establishing commercial infrastructure for ELZONRIS; product efficacy or safety concerns resulting in product recalls or regulatory action; the risk that estimates regarding the number of patients with the diseases that our product and product candidates may treat are inaccurate; inadequate market penetration of our products; our products not gaining acceptance among patients (and providers or third party payors) for certain indications (due to cost or otherwise); the risk that third party payors (including governmental agencies) will not reimburse for the use of ELZONRIS at acceptable rates or at all; the companys ability to produce, maintain or increase sales of ELZONRIS; the companys ability to develop and/or commercialize ELZONRIS; the adequacy of our pharmacovigilance and drug safety reporting processes; our available cash and investments; our ability to obtain and maintain intellectual property protection for our product and product candidates; delays, interruptions, or failures in the manufacture and supply of our product and product candidates; the performance of third-party businesses, including, but not limited to, manufacturers, clinical research organizations, clinical trial sponsors and clinical trial investigators; and other risk factors identified from time to time in our reports filed with the SEC. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

Contact: Investor RelationsStemline Therapeutics, Inc.750 Lexington AvenueEleventh FloorNew York, NY 10022Tel: 646-502-2307Email: investorrelations@stemline.com

See the original post:
Stemline Therapeutics Announces Preliminary 2019 Net Revenues for ELZONRIS (tagraxofusp) and Highlights Commercial and Clinical Growth Drivers -...

Magenta Therapeutics Advances Conditioning Platform and Clinical Programs, Highlights Recent Milestones and 2020 Goals – Yahoo Finance

Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today highlighted recent progress across several programs and outlined goals for 2020. These updates will be discussed during a webcast presentation at the 38th annual J.P. Morgan Healthcare Conference on Wednesday, January 15th at 11:30 a.m. PT (2:30 p.m. ET).

"In 2019 we generated landmark data from our ADC-based targeted patient preparation platform, which is delivering a new class of antibody-drug conjugates (ADCs) that have the power to bring one-time treatment to more patients with autoimmune diseases, blood cancers and genetic diseases. We also presented clinical data for our first-line stem cell mobilization program, MGTA-145, which we are developing as the new standard of care for stem cell mobilization with the potential to benefit all of the transplant-eligible patients each year," said Jason Gardner, D. Phil., President and Chief Executive Officer, Magenta. "As we begin 2020, we are particularly excited to unveil our MGTA-117 clinical candidate for targeted patient preparation for stem cell transplant or gene therapy. New results announced today highlight the potency, safety and broad therapeutic index of MGTA-117, well above that of currently approved ADCs. We believe that MGTA-117 is the optimal agent for depleting stem cells to enable safe immune reset. We look forward to moving this program into the clinic with initial clinical data expected in 2021."

Targeted Patient Preparation Programs

Current methods to condition patients before transplant and gene therapy are dependent on toxic, non-specific chemotherapy or radiation. These pre-transplant treatments are associated with significant side effects, including infertility, cancer, organ damage and death. Magenta is developing targeted, disease-modifying ADCs that are designed to precisely and rapidly remove the disease-causing cells in the body and enable immune system reset without the need for chemotherapy or radiation.

CD117-ADC Recent Progress

Data presented at the American Society of Hematology (ASH) annual meeting in December 2019, showed the first-ever successful transplant of gene-modified cells in non-human primates using a CD117-targeted, single-agent ADC from Magenta, without the use of chemotherapy or radiation. These unprecedented results validate and advance Magentas conditioning platform.

Building on this work, Magentas new clinical candidate, MGTA-117, is a CD117 antibody conjugated to amanitin. Results published today in an abstract for the Transplant and Cellular Therapy annual meeting show that MGTA-117 potently depleted stem and progenitor cells and demonstrated a wide tolerability: potency ratio of 30 fold (therapeutic index; typical range for approved ADCs at this stage is two to six fold). This program is advancing to the clinic and further validates Magentas antibody drug conjugate-based conditioning platform. MGTA-117 was developed under a partnership with Heidelberg Pharma that grants Magenta exclusive worldwide development and marketing rights for ADCs using an amanitin payload and targeting CD117.

MGTA-117 in 2020

Magenta is scaling up manufacturing of MGTA-117 and completing IND-enabling studies in 2020. The Company intends to move this new product candidate into the clinic with initial clinical data expected in 2021.

CD45-ADC Recent Progress

Current standard treatment for patients with multiple sclerosis involves years of chronic dosing of medications that do not halt the progression of the disease. For patients with systemic sclerosis, a potentially fatal autoimmune disease, there are no approved therapies. Immune reset through stem cell transplant has demonstrated durable remissions in thousands of patients with autoimmune diseases such as multiple sclerosis and systemic sclerosis, and it is recommended by the European League Against Rheumatism (EULAR) in treatment guidelines for systemic sclerosis. The immune reset process involves two main steps: removing the disease-causing cells and replacing them with healthy cells to rebuild the immune system to a healthy state.

Magenta is developing targeted ADCs designed to precisely remove the disease-causing cells in the body without the need for chemotherapy or radiation. Magentas CD45-ADC program targets CD45, a protein expressed on immune cells and stem cells and is designed to remove the cells that cause autoimmune diseases in order to enable curative immune reset.

Story continues

Data presented at the American College of Rheumatology (ACR) meeting in November 2019 showed that a single dose of CD45-ADC removed disease-causing reactive T cells, enabled successful immune reset and rebuild of the immune system and was well tolerated in three models of autoimmune disease, including the EAE model, the most reliable murine model of multiple sclerosis. Further, a single dose of CD45-ADC significantly reduced disease incidence and delayed disease onset in this model that has successfully provided preclinical proof of concept for many clinically validated standard-of-care therapies.

CD45-ADC in 2020

Magenta has identified a lead antibody and has progressed this program into IND-enabling studies, which the Company plans to further advance in 2020.

MGTA-145 First-Line Stem Cell Mobilization Therapy

MGTA-145 Recent Progress

Magenta is developing MGTA-145 as the new first-line standard of care for stem cell mobilization in a broad range of diseases, including autoimmune diseases, blood cancers and genetic diseases. MGTA-145, a CXCR2 agonist, works in combination with plerixafor, a CXCR4 antagonist, to harness the physiological mechanism of stem cell mobilization.

Magenta is currently studying MGTA-145 and plerixafor in a Phase 1 study in healthy volunteers. Data from the Phase 1 study presented at the ASH annual meeting in December 2019 showed that MGTA-145 in combination with plerixafor successfully enables safe, same-day dosing, mobilization and collection of sufficient high-quality hematopoietic stem cells for transplant. Further, when cells collected from the first two apheresis subjects were transplanted into humanized mice, the cells engrafted more rapidly and at a five-fold higher level than cells from G-CSF-mobilized peripheral blood.

MGTA-145 in 2020

Magenta intends to complete the Phase 1 study and move this program into multiple Phase 2 studies in patients in 2020. The Phase 2 studies will include both allogeneic and autologous transplant settings and will evaluate mobilization and collection of high-quality cells and engraftment of the cells after transplant.

MGTA-456 Cell Therapy

MGTA-456 Recent Progress

MGTA-456 is a cell therapy designed to provide a high dose of stem cells that are well matched to the patient to enable safe immune and blood system rebuild and durable remissions in patients with blood cancers. In September, the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation for MGTA-456 for the treatment of multiple inherited metabolic disorders.

Magenta is currently studying MGTA-456 in a Phase 2 study in patients with inherited metabolic disorders, including cerebral adrenoleukodystrophy (cALD) and Hurler syndrome. These are rare, rapidly progressive neurologic disorders that are fatal when left untreated. Results in the first two evaluable patients with cALD updated in December 2019 showed early and durable resolution of the disease at 12 months follow-up. The Loes score and NFS score, which measure progress of the disease, remained stable, suggesting that progress of the disease has been halted in these patients. The early and durable resolution of disease with MGTA-456 is not consistently seen with other therapies, including standard stem cell transplant, gene therapy or enzyme replacement therapy.

MGTA-456 in 2020

Magenta intends to complete enrollment in the Phase 2 in 2020 and continue dialogue with the FDA under the RMAT designation, and to discuss with the European Medicines Agency (EMA) for development in Europe

About Magenta Therapeutics

Headquartered in Cambridge, Mass., Magenta Therapeutics is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune diseases, blood cancers and genetic diseases. By creating a platform focused on critical areas of unmet need, Magenta Therapeutics is pioneering an integrated approach to allow more patients to receive one-time, curative therapies by making the process more effective, safer and easier.

Forward-Looking Statement

This press release may contain forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "may," "will," "could", "should," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "seeks," "endeavor," "potential," "continue" or the negative of such words or other similar expressions can be used to identify forward-looking statements. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation risks set forth under the caption "Risk Factors" in Magentas Annual Report on Form 10-K, as updated by Magentas most recent Quarterly Reports on Form 10-Q and its other filings with the Securities and Exchange Commission. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although Magenta believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither Magenta nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200113005308/en/

Contacts

Magenta Therapeutics:Manisha Pai, Vice President, Communications & Investor Relations617-510-9193mpai@magentatx.com

Read more here:
Magenta Therapeutics Advances Conditioning Platform and Clinical Programs, Highlights Recent Milestones and 2020 Goals - Yahoo Finance

AgeX Therapeutics to Participate at Four Conferences in January 2020 – Yahoo Finance

AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today that the company will present at the following four conferences this month: Biotech Showcase, January 13-15; Precision Medicine World Conference (PMWC 2020), January 21-24; World Stem Cell Summit, January 21-24; and Longevity Therapeutics, January 28-30.

Details of the companys presentations follow:

Biotech Showcase January 13-15 at the Hilton San Francisco Union Square, San Francisco, CaliforniaAgeX session: Wednesday, January 15, 9:00am PST.

AgeXs founder and CEO Michael D. West, PhD will deliver a presentation on AgeX and its programs at this investor conference held concurrently with the J.P. Morgan Healthcare Conference.

World Stem Cell Summit January 21-24 at the Hyatt Regency Miami, Miami, Florida.

AgeX will participate in a 90-minute session that will include two talks as well as a panel discussion, on Thursday, January 23, 1:45-3:15pm EST. Dr. West will deliver a 25-minute presentation, "Towards safe in vivo partial reprogramming with induced tissue regeneration" while AgeXs VP, Discovery Research, Dana Larocca, PhD, will deliver a presentation, "Derivation and uses of highly pure, non-immunogenic lineage-specific stem cell lines."

Additionally, three AgeX team members will participate on a panel discussion, "The next stem cell revolution: transcending limits on purity, immunogenicity and oncogenicity." Panel participants include Drs. West and Larocca, in a session moderated by Dr. Aubrey de Grey, AgeXs VP, New Technology Discovery.

Precision Medicine World Conference (PMWC 2020) January 21-24 at the Santa Clara Convention Center, Santa Clara, CaliforniaAgeX Session: Thursday, January 23, 3:30pm PST.

AgeXs CFO Russell Skibsted will deliver a corporate presentation as part of the Emerging Therapeutics Track.

Longevity Therapeutics January 28-30 at the Holiday Inn Golden Gateway Hotel, San FranciscoAgeX session: Wednesday, January 29, 1:30pm PST.

Dr. Larocca will deliver a presentation on AgeXs induced tissue regeneration (iTR) program.

About AgeX Therapeutics

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly-defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeXs revolutionary longevity platform induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem is AgeXs delivery technology to stably engraft PureStem cell therapies in the body. AgeX is developing its core product pipeline for use in the clinic to extend human healthspan and is seeking opportunities to establish licensing and collaboration agreements around its broad IP estate and proprietary technology platforms.

For more information, please visit http://www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.

Forward-Looking Statements

Certain statements contained in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates" should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the "Risk Factors" section of AgeXs Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commissions (copies of which may be obtained at http://www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200114005342/en/

Contacts

Media Contact for AgeX:

Bill Douglass Gotham Communications, LLCbill@gothamcomm.com (646) 504-0890

See original here:
AgeX Therapeutics to Participate at Four Conferences in January 2020 - Yahoo Finance

Imber Medical has what we’ve all been waiting for – Brunswick News

The word enthusiasm comes to mind when you meet Dr. Slack, MD and her team. Even the building itself has an air of newness and excitement. Dr. Slack begins to tell me about what is available at Imber and Im surprised that I have never heard of several of these treatments.

I see her face light up as she explains how much these treatments have helped people. And that for some, aesthetics treatments can be better than Prozac! The latest treatment acquired is the EMSCULPT. This is a machine that uses magnetic energy to initiate contractions of the muscles 20,000 contractions in 30 minutes to be exact!

This leads to formation of new muscle fibers and improvement in core strength that continues for years! Studies show that EMSCULPT not only increases muscles but induces 20% fat reduction (as a glorious side effect). These results have been confirmed by MRIs so there is no guesswork as to the devices effectiveness. What is amazing about this machine is that you get the benefits of doing 20,000 sit-ups while lying down and relaxing. No sweating, no pain, no shortness of breath or increase in heart rate.

This is a fantastic option for anyone who has trouble building up their muscles because of time constraints, back pain, child- birth or even hitting that dreaded plateau at the gym. Ladies love the flat stomachs, toned abs and improvements in physical ability appreciated during yoga, pilates, and tennis! Men have become huge fans after seeing how the results of strengthening ones core affects their golf game!

We first realized there was a demand for EMSCULPT in the Golden Isles when several existing clients expressed how much it had helped their back pain when treated with EMSCULPT at an Atlanta clinic says Dr. Slack. What sold our team was the before and after pictures which speak for themselves. But I was even more impressed with the data and shocked to learn that this device is the only non-surgical, FDA approved option for treatment for diastasis recti (the separation of stomach muscles that occurs during pregnancy). Life brings a lot of changes and how we look, and feel can greatly impact our confidence. What Imber offers is the latest solutions that are proven to work.

EMSCULPT is also FDA approved for building the muscles of the abs, glutes, arms and legs. I cant help but think that this is the perfect time of year. Valentines Day, and shorts season will be here before we know it!

Dr. Slack goes on to list other novel treatments. She shares with me information on Verju, a FDA approved, pain-free, non-surgical, fat reducing (non-hot, non- cold) laser. That consistently delivers results of 4 inch overall circumference reduction after just 6 treatments.

If that wasnt enough to blow my mind she went on to tell me about PDO Threads. She describes how these FDA approved threads can lift the face and smooth out wrinkles while building collagen. Plasma Pen was mentioned next. which is an FDA approved treatment for a non-surgical eyelid lift and wrinkle removal. PRP (Platelet Rich Plasma) is another option in the fight to revitalize the skin. Like the Plasma Pen, PRP is 100% natural and organic which is important to the Imber team!

Even the staples of aesthetics like Botox and filler treatments are taken to a whole new level. Dr. Slack is so proud of her team consisting of herself as an aesthetics board certified MD and advanced registered nurse practitioners. Imbers master injector, Bianca Trevino ARNP, is also board certified in aesthetics and able to provide Botox injections in areas I had never heard of! She can upturn the corners of a down turned mouth, lower the lip of a gummy smile, prevent the tip of a nose from pulling down, provide brow lifts, jaw definition, fine line and wrinkle reduction with micro-Botox and even eliminate neck bands! With regard to filler, the advanced training really shows with their results in providing a natural and youthful appearance, never looking overdone. Imber has virtually every toxin and filler available and the knowledge of what needs to be used when. Bioidentical hormone therapy, IV hydration therapy, hair restoration for men and women, intimacy treatments, jaw contouring, medical assisted weight loss, scar revision, acne treatment and so much more is offered at Imber.

When combining the above treatments with medical grade products (including stem cell and sun protection) sold at Imber: prevention, correction and maintenance are all optimized.

In finishing up my visit, Dr. Slack tells me Our clinics goal is to provide the latest FDA approved solutions available to help all of the Golden Isles look and feel like the best version of themselves. We are so blessed to be a part of this wonderful community and look forward to giving it the best the World has to offer.

If you would like to learn more, Imber hosts a Thirsty Thursday event every 3rd Thursday of the month for those who Thirst for Knowledge ...or wine! Join Imber Jan 16th to learn more about Emsculpt or any other services Imber offers!

Excerpt from:
Imber Medical has what we've all been waiting for - Brunswick News

Tacitus Therapeutics Launches in Collaboration with Mount Sinai to Develop Stem Cell Therapies for Life-Threatening Diseases – Yahoo Finance

Tacitus Therapeutics exclusively licenses technology for expansion, differentiation and engineering of hematopoietic stem cells for use in therapeutic applications

NEW YORK, Jan. 9, 2020 /PRNewswire/ -- Tacitus Therapeutics, a clinical-stage company, has launched in collaboration with the Mount Sinai Health System to develop stem cell therapies initially targeting blood cancers and related clotting disorders. Their first therapy, HSC100, currently is being investigated in a Phase I clinical trial1.

Tacitus is building upon technology developed by and exclusively licensed from Mount Sinai. Based on research by scientific co-founders Ronald Hoffman, M.D., and Camelia Iancu-Rubin, Ph.D., the technology includes proprietary cell expansion, differentiation and engineering methods. Together, these methods manufacture healthy cells that overcome the limitations of traditional allogeneic, or donor, cell transplantations.

Blood cancers comprise about 10% of new cancer cases in the U.S. each year, and almost 60,000 people die from blood cancer complications annually. Most blood cancers start in the bone marrow, where blood is produced. A common therapy for such blood cancers is a hematopoietic stem cell (HSC) treatment or, as more commonly referred to, bone marrow transplantation. In this process, doctors infuse healthy HSCs into the patient's bloodstream, where they migrate to the bone marrow to grow or engraft.

HSCs for this process can be collected from bone marrow, circulating blood, or umbilical cord blood (CB) of healthy donors. While HSC transplants are common, significant barriers to success exist, including high levels of graft-versus-host disease, low numbers of healthy cells obtained from CB, and increased risk of bleeding due to delayed megakaryocyte, or platelet, engraftment.

Hoffman and Iancu-Rubin are pioneers of bone marrow cell therapy treatments, and development of this technology was enabled by the New York State Stem Cell Science program, NYSTEM. As a New York State Department of Health initiative, NYSTEM awarded a $1 million grant to Hoffman in 2010 that supported the original research underpinning this platform technology. In 2015, NYSTEM awarded Hoffman and Iancu-Rubin an $8 million grant to translate the technology from the laboratory into the clinic, where it is currently in clinical trial1.

Hoffman also serves as Director of the Myeloproliferative Disorders Research Program and Professor of Medicine (Hematology and Medical Oncology) and Iancu-Rubin is Associate Professor of Pathology at the Icahn School of Medicine and Director of the Cellular Therapy Laboratory at Mount Sinai Hospital.

"Promising discoveries by Mount Sinai scientific thought leaders may lead to new, essential cell-based therapies that will broadly benefit patients," said Erik Lium, Executive Vice President and Chief Commercial Innovation Officer, Mount Sinai Innovation Partners. "We're pleased to be collaborating with Tacitus to launch the next stage of development for these technologies."

"Tacitus is committed in its mission to advance next-generation cell therapies with curative potential," said Carter Cliff, CEO of Tacitus. "Based on our founders' solid foundation of research, we are translating these discoveries into broad clinical practice as we look to dramatically improve the standard of care for patients with life-threatening conditions."

About HSC100

HSC100 is an investigational therapy based on allogeneic hematopoietic stem cells (HSC) expanded from umbilical cord blood. HSC100 is being investigated currently in an open-label Phase I clinical trial1 in the United States for treatment of hematological malignancies. The success of unmanipulated cord blood as a source of stem cells has been hampered by the small number of stem cells present in a single cord, leading to delayed engraftment and frequent graft failure. Our proprietary technology includes the use of an epigenetic modifier, valproic acid, to expand the number and the quality of HSCs found in cord blood collections. For more information on HSC100 clinical trials, please visit http://www.clinicaltrials.gov.

1ClinicalTrials.gov identifier NCT03885947.

About Tacitus Therapeutics

Tacitus Therapeutics is a clinical-stage biotechnology company developing advanced medicines for treatment of blood cancers, immune disorders and other intractable disease conditions. Our mission is to pioneer best-in-class therapies using proprietary cell expansion, differentiation and engineering platform technologies that overcome the limitations of traditional cell transplantation. Initial targets include a lead clinical program (HSC100) investigating the treatment of blood cancers, followed by preclinical programs to address clotting disorders and other serious unmet medical needs. For additional information, please visit http://www.tacitustherapeutics.com.

Story continues

About Mount Sinai Health System

The Mount Sinai Health System is New York City's largest integrated delivery system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai's vision is to produce the safest care, the highest quality, the highest satisfaction, the best access and the best value of any health system in the nation. The Health System includes approximately 7,480 primary and specialty care physicians; 11 joint-venture ambulatory surgery centers; more than 410 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. The Icahn School of Medicine is one of three medical schools that have earned distinction by multiple indicators: ranked in the top 20 by U.S. News & World Report's "Best Medical Schools", aligned with a U.S. News & World Report's "Honor Roll" Hospital, No. 12 in the nation for National Institutes of Health funding, and among the top 10 most innovative research institutions as ranked by the journal Nature in its Nature Innovation Index. This reflects a special level of excellence in education, clinical practice, and research. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report's "Honor Roll" of top U.S. hospitals; it is one of the nation's top 20 hospitals in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Geriatrics, Gynecology, Nephrology, Neurology/Neurosurgery, and Orthopedics in the 2019-2020 "Best Hospitals" issue. Mount Sinai's Kravis Children's Hospital also is ranked nationally in five out of ten pediatric specialties by U.S. News & World Report. The New York Eye and Ear Infirmary of Mount Sinai is ranked 12th nationally for Ophthalmology, Mount Sinai St. Luke's and Mount Sinai West are ranked 23rd nationally for Nephrology and 25th for Diabetes/Endocrinology, and Mount Sinai South Nassau is ranked 35th nationally for Urology. Mount Sinai Beth Israel, Mount Sinai St. Luke's, Mount Sinai West, and Mount Sinai South Nassau are ranked regionally. For more information, visit http://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.

About Mount Sinai Innovation Partners (MSIP)

MSIP is responsible for driving the real-world application and commercialization of Mount Sinai discoveries and inventions and the development of research partnerships with industry. Our aim is to translate discoveries and inventions into health care products and services that benefit patients and society. MSIP is accountable for the full spectrum of commercialization activities required to bring Mount Sinai inventions to life. These activities include evaluating, patenting, marketing and licensing new technologies building research, collaborations and partnerships with commercial and nonprofit entities, material transfer and confidentiality, coaching innovators to advance commercially relevant translational discoveries, and actively fostering an ecosystem of entrepreneurship within the Mount Sinai research and health system communities. For more information, please visit http://www.ip.mountsinai.orgor find MSIP onLinkedIn, Twitter, Facebook,Medium, and YouTube.

Media Contacts:

Mount Sinai Cynthia Cleto Mount Sinai Innovation Partners (646) 605-7359 cynthia.cleto@mmsm.edu

Tacitus TherapeuticsJoleen RauRau Communications(608) 209-0792232130@email4pr.com

View original content:http://www.prnewswire.com/news-releases/tacitus-therapeutics-launches-in-collaboration-with-mount-sinai-to-develop-stem-cell-therapies-for-life-threatening-diseases-300984051.html

SOURCE Tacitus Therapeutics

See more here:
Tacitus Therapeutics Launches in Collaboration with Mount Sinai to Develop Stem Cell Therapies for Life-Threatening Diseases - Yahoo Finance

‘Comfort’ or con? Despite money, education, well-off Filipinos turning to questionable treatments – Coconuts

In 2008, retired finance professional Pablito Bermundo found himself staring up at the surgical lighting hanging over the operating table, feeling both annoyed and amused that he was once again going under the knife.

After his gallbladder was removed in 2006, a massive cyst grew in his liver, one that would need to be surgically drained every six months. After two years of being wheeled in and out of the operating room, he decided that hed had enough.

I have to look for other options, he thought.

In 2009, Bermundo met a man who convinced him to give hilot a shot. Hilot is an ancient Filipino healing method in which ailments are purportedly treated with massages administered by healers known as manghihilot, who supposedly derive their power from God. Though many doctors are skeptical that hilot can cure serious illnesses, Bermundo credits it with saving his life.

With standards of living and education levels on the rise across much of Southeast Asia, including the Philippines, it would stand to reason that traditional healing methods often scientifically dubious, and occasionally accused of making matters worse would have begun to wane outside of remote areas where traditional ways still hold sway. However, Bermundo is one of many middle- and upper-class Filipinos who, despite their means and access to modern treatments, have continued to put their faith in alternative healing methods over Western medicine.

Meanwhile, as access to science-based Western medicine increases, so too does exposure to Western quackery, and questionable new-age healing practices many of which have quasi-Orientalist roots, and have been debunked by science are also beginning to make inroads among well-off Filipinos.

A gift from the gods

Though finding figures on alternative medicine use is next to impossible, medical anthropologist and physician Dr. Gideon Lasco says that the embrace of alternative treatments transcends class.

People just go to different places. For example, our fellow Filipinos in far-flung areas might go to an albularyo [a traditional healer], whereas a millionaire might fly into some Indian [retreat], or see some Korean practitioner.

He said people have different reasons for being wary of modern treatments.

Some people might have previous experience in hospitals or [with] doctors that they didnt enjoy.

In Bermundos case, what pushed him to go for hilot was his unhappiness with the options Western medicine and health professionals were presenting him.

I sought a second, third opinion. One doctor said he could cut off the cysts [because he said the liver] would still regenerate, he said, adding that to him, the treatment sounded too invasive.

But that all changed when he met the late Boy Fajardo, a manghihilot who learned the treatment through apprenticeships with rural healers he met in his travels around the Philippines.

Bermundo felt he had nothing to lose by trusting the healer, and Fajardo put him through regular weekly hilot sessions, and made him drink an herbal concoction containing water spinach and banaba leaves after every meal. After one month under Fajardos care, Bermundo went for an ultrasound and was pleasantly surprised to see that his cyst had shrunk dramatically.

Bermundo recalls his doctor telling him, There are no scientific studies that prove that hilot works, but just continue what youre doing.

Fajardo passed away in 2018, but Bermundo, now 76, still goes for hilot sessions, and remembers the healer as a charming man who was easy to trust.

He was naturally friendly; he wasnt in a hurry. He would answer all of your questions; you can call him anytime.

Fajardos protg Louanne Calipayan told Coconuts Manila that kindness was an especially important requirement for a manghihilot, and not just because it improves their bedside manner.

They have to be good people because what they offer is a service. A healer needs to have this characteristic because [we believe] he channels the energy from a Supreme Being, she said. A healer has to change whats in his heart because thats the energy that he will channel out of himself.

Calipayan said that despite the advancements modern medicine has made, she and her associates are seeing a resurgence in interest in hilot.

We have people flying in from Visayas and Mindanao and all other parts of Luzon. These are not the stereotypical people who go for hilot, who are uneducated or dont have money to pay a doctor, she said. In many cases, these are people who have been to many doctors or have had different treatment options, but they found the relief they were looking for in hilot.

Its not just Filipino patients who are becoming increasingly interested in hilot. As with other Eastern medicinal practices of unproven efficacy like Indias Ayurvedic healing, for instance hilot is attracting attention among Westerners. Calipayan said that not only has she has trained students from all over the country on how to practice hilot, she has also had some from as far away as Canada.

Medical anthropologist Lasco said he was skeptical of the actual medical benefits of hilot, but allowed there was still a lot of things doctors could stand to learn from traditional healers like Fajardo and Calipayan.

Patients dont just go to a doctor to get a diagnosis or treatment. They also go to the doctor to get comfort, to get reassurance, to understand whats happening to their bodies, to be given a chance to discuss choices, he said.

These traditional medicine practitioners offer us a clue of what patients are looking for. These hilot, albularyo what they offer is a personal connection.

He died of sadness

But for every apparent alternative healing success story like Bermundos, theres another like J.B. Bolaos.

A publicist by trade, Bolaos had grown skeptical of Western medicine after he witnessed what it did to his late mother, Lina.

In a recent phone interview, J.B. told Coconuts Manila how he lost both of his parents, starting with Lina, who died of lung cancer in March of 2018 after a grueling course of chemotherapy that ravaged her body. When his father, Melecio, was diagnosed with pancreatic cancer, he looked for another option.

I saw what chemo did to my mom. Every three weeks we would fly to China for cryosurgery, and chemo. She would feel so weak after two days, he recalled. [Thats why I thought] I would not go for conventional therapy for my father.

J.B. explained that based on his research, pancreatic cancer has a very poor prognosis, which further pushed him to try alternative means for his father. Chemo, he believed, would have just made Melecio weaker.

Melecio went through an alternative treatment called Gerson therapy, a dietary regimen devised by the German-American physician Max Gerson, who began touting it as an effective alternative cancer treatment in the 1920s. In Gerson therapy, patients adhere to a strict diet, purportedly to flush out toxins, and are also given coffee enemas, supposedly to spur the production of glutathione, a detoxifying antioxidant.

However, by 1989, the American Cancer Society had already evaluated the treatment and labeled Gerson therapy a sham, finding no evidence that it could effectively treat cancer. Prior to that, the National Cancer Institute in the United States studied 60 patients who used the Gerson therapy between 1947 and 1959, and concluded that the regimen did not benefit those patients.

More recently, an Australian wellness blogger documented her own rejection of more aggressive cancer treatment in favor of Gerson therapy. Despite consuming 10 juices and undergoing five coffee enemas a day as part of the regimen, she died at age 30 in 2015.

Despite the questionable nature of the treatment, J.B. and his father decided to try the method, which proved equally as expensive and taxing as chemotherapy.

Its all about juicing, the right diet, where everything has to be organic, J.B. explained. He had to take around nine juices a day, but theyre organic. All are fresh. You cannot prepare the juice like two hours before [you drink them]; you have to prepare them on the spot.

Because J.B. was busy managing his own company while juggling a teaching career, he had to hire two nurses who worked in shifts to take care of his father. Aside from the organic juices, his father was also infused with high doses of Vitamin C, Vitamin B17, and Chinese herbal medicines, and underwent ozone therapy, an alternative treatment that supposedly increases the amount of oxygen in the body.

Melecio ultimately passed away, but his son still believes that the treatment he received gave him the best quality of life.

Conventional [chemo] therapy would have given him no assurance that he would win the battle against cancer, J.B. said. There were no assurances; in fact, he might have died sooner.

My dad died of heart failure. Normally, if you die of cancer, its multiple organ failure. What he died from was totally unrelated. His heart just stopped. And I know that when someone has pancreatic cancer when you hold that persons hand, they would feel pain. My dad never had that experience, he added.

He died of sadness [from my mothers passing]. I would like to believe that he did not die of cancer.

Lasco, the medical anthropologist, said a belief in alternative treatments is common among those who have been diagnosed with cancer because of the high rate of mortality. Ditching chemotherapy as JB did for his father is understandable given the extreme side effects.

Its natural for us to want to live as long as we can, but for other people, their priority is their quality of life. They would rather have a normal and non-chemotherapy kind of life and think, OK, Ill risk this treatment. If it doesnt work out, thats OK with me, he said.

Still, as a physician, Lasco would not recommend alternative treatments to his own family.

People have their own reasons [for using such treatments]I dont want to debate [against them] because its easy to find someone who died due to chemotherapy, he said.

Whether we like it or not, we are mortals and one way or another, we will all die. So the best thing we can do [as doctors] is to show patients that this kind of treatment, based on a global study, has a recovery rate of this percentage.

Profiting on pain

Lasco, however, remains worried about fraudulent healers who take advantage of patients desperate to find a cure for their terminal illnesses, specifically cancer.

The country is no stranger to such charlatans. In the 1970s, for example, the Philippines became known for its psychic healers and those who claimed to be able to perform surgery with their bare hands. The most famous of them, Ramon Jun Labo, even treated the late comedian Andy Kaufman and then-President Ferdinand Marcos. Labo was later sued for swindling in Moscow by thousands of his former clients.

Another high-profile alternative healer was Antonia Park, who admitted to Rappler in 2014 that she was not a registered physician in the Philippines, despite working as a stem cell doctor for former President Gloria Macapagal Arroyo and the late Quezon City Vice Mayor Charito Planas.

Park was sued by businessman Bernard Tan in 2013 after Park treated his late daughter, Kate Tan, whose cancer recurred in 2012.

According to Bernard, Park said his daughter was just suffering from a hormonal imbalance and promised to treat her within three months through stem cell therapy, Rappler reported. Park also put Kate on a restrictive diet featuring fruit and vegetable juices. But as the months passed, Bernard noticed that his daughter was not getting any better.

Kate ultimately went back to chemotherapy and died in July 2013, with Bernard blaming Park for her death. Park was charged with fraud and reckless imprudence resulting in homicide, and her clinic was shut down by the authorities.

Lasco said that despite peoples understandable motivations for seeing alternative treatments, there is a need to protect patients and their families from healers of questionable backgrounds, without dismissing the legitimate fears and concerns of patients.

We should be vigilant about how peoples desperation [is] being used by these alternative providers. Our regulatory agencies should go after these treatments, Lasco said.

People dont want to give up that easily, and they will avail of treatments, especially these treatments offered by people who offer them hope. Ive seen it happen that theyre taken advantage of, he noted. Theres no way to prove if these treatments work or not because people dont complain because theyre dead.

Read more Coconuts Manila feature stories here.

Read the original post:
'Comfort' or con? Despite money, education, well-off Filipinos turning to questionable treatments - Coconuts

Doctor’s Hospital focused on incorporation of AI and machine learning – EyeWitness News

NASSAU, BAHAMAS Doctors Hospital has depriortized its medical tourism program and is now more keenly focused on incorporating artificial intelligence and machine learning in healthcare services.

Dr Charles Diggiss, Doctors Hospital Health System president, revealed the shift during a press conference to promote the 2020 Bahamas Business Outlook conference at Baha Mar next Thursday.

When you look at whats happening around us globally with the advances in technology its no surprise that the way companies leverage data becomes a game changer if they are able to leverage the data using artificial intelligence or machine learning, Diggiss said.

In healthcare, what makes it tremendously exciting for us is we are able to sensorize all of the devices in the healthcare space, get much more information, use that information to tell us a lot more about what we should be doing and considering in your diagnosis.

He continued: How can we get information real time that would influence the way we manage your conditions, how can we have on the backend the assimilation of this information so that the best outcome occurs in our patient care environment.

Diggiss noted while the BISX-listed healthcare provider is still involved in medical tourism, that no longer is a primary focus.

We still have a business line of medical tourism but one of the things we do know pretty quickly in Doctors Hospital is to deprioritize if its apparent that that is not a successful ay to go, he said.

We have looked more at taking our specialities up a notch and investing in the technology support of the specialities with the leadership of some significant Bahamian specialists abroad, inviting them to come back home.

He added: We have depriortized medical tourism even though we still have a fairly robust programme going on at our Blake Road facility featuring two lines, a stem cell line a fecal microbiotic line.

They are both doing quite well but we are not putting a lot of effort into that right now compared to the aforementioned.

Read more here:
Doctor's Hospital focused on incorporation of AI and machine learning - EyeWitness News

Viewpoints: Medicaid Expansion Reveals How Liberal Policies Make For Good Politics; Hey, Congress, What’s The Hold Up With Surprise Medical Bills? -…

Opinion writers tackle these and other health issues.

The New York Times:Progressives Are The Real PragmatistsWhen left-wing Democrats push for universal benefits and expansive new policies, they do so with a theory of politics in mind. It goes like this: The reason to fight for debt-free college or Medicare for all isnt just to improve life for Americans, but to build new ground for progressive political activity. New programs create new constituencies, and new programs with broad benefits can give more Americans a stake in the expansion and preservation of the welfare state. Conservatives know this. Thats why theyve fought so hard to block or undermine even modest new programs. (Jamelle Bouie, 1/13)

The Washington Post:Congress Needs To Settle Its Differences And Put An End To Surprise Medical BillingWashington seemed to be working, for once. Last month, key members of the House and Senate House Energy and Commerce Committee Chairman Frank Pallone Jr. (D-N.J.), Rep. Greg Walden (R-Ore.), Senate Health Committee Chairman Lamar Alexander (R-Tenn.) and Sen. Patty Murray (D-Wash.) had negotiated legislation that would end so-called surprise medical billing. Example: when you have emergency surgery, then get slammed unexpectedly with a huge bill from an out-of-network anesthesiologist you didnt choose. The legislation was set to be included last month in a must-pass funding bill. (1/12)

Cleveland Plain Dealer:There Is No Excuse For Surprise Medical Billing. Ohio Should Act.Voters concerned about surprise billing should let those legislators know of their concerns, and share any personal experiences with surprise billing that theyve had. According to a report by the Commonwealth Fund (a philanthropy founded by the Harkness family, which had Cleveland ties), as of July, 28 states had enacted measures to protect patients against surprise medical billing.Ohio should do the same. (1/10)

The Hill:Where Women's Health Care Is Lacking, Women Are DyingA woman is more likely to die of cervical cancer in Alabama than in any other state in the country. An African-American woman in the state is twice as likely to die of cervical cancer than a white woman.While these statistics are harrowing, they are not surprising. Alabamas disproportionately high cervical cancer mortality rate is reflective of a more significant trend: States that limit access to womens health services tend to have the worst health outcomes for women. (Nakisa B. Sadeghi and Dr. Leana S. Wen, 1/10)

Colorado Sun:We Are Colorado ObGyns. Words Matter On Abortion Rights.If pregnant people and a medical procedure are going to be used as fodder for a political dispute, we all have an obligation to get the medical science and facts right. That means relying on doctors and medical professionals for their expertise, not politicians who are trying to use stigma, shame and inflammatory language to keep pregnant people from exercising their constitutional rights. Recently, Facebook took down a fact check of an anti-abortion video by three doctors after four male Republican senators objected. Thats not OK. (Dr Emily Schneider and Dr. Kristina Tocce, 1/12)

The Washington Post:I Thought My Second Baby Would Be Easier. And Then I Started Drowning.After four years, three miscarriages and an ectopic pregnancy, the second baby I had yearned for entered the world. Armed with four years of parenting experience, I thought I was better equipped to handle life with a newborn than I had been as a new mom. I had survived the sleepless nights, weathered the scary fevers that precede budding teeth and coached myself through the irrational fears that accompany caring for a completely helpless human. (Danielle Campoamor, 1/10)

Bloomberg:Obamacare Marches On As Republicans FlailState by state, my prediction that the Medicaid expansion made possible by the Affordable Care Act would eventually be universal is slowly coming true. Most Republican governors had originally rejected expansion and the federal money that finances it, but plenty of them are agreeing to compromises to make it happen. The latest? Kansas. That leaves 14 states to go, although those 14 still include both Texas and Florida, so were still talking about a lot of uninsured people. (Jonathan Bernstein, 1/10)

The New York Times:The F.D.A. Is In Trouble. Heres How To Fix It.The Food and Drug Administration is in distress. The agency is still the worlds leading regulator of food and medical products, responsible for ensuring the safety of some $2.6 trillion in consumer goods each year. That represents 20 cents of every dollar that Americans spend. But critics both inside and outside the sprawling agency say that the F.D.A.s standards have been slipping for some time. (1/11)

The Hill:China Has A New SARS-Like Virus How Serious Is It?The last several days of infectious disease headlines have been focused on a mysterious outbreak in Wuhan, China, that has many concerning harbingers. This cluster of pneumonia cases some of which are severe involves individuals who had exposure to a, since decontaminated, seafood market that housed many types of animals. (Dr. Amesh Adalja, 1/9)

The Washington Post:Puerto Ricans Should Never Forget How Trump Treated ThemHere's what Puerto Rico has endured over the past two years: a devastating hurricane that killed and displaced thousands of people and plunged the island into months of darkness; an incompetent and corrupt local government; a bungled and halfhearted emergency response from the federal government. Now, even as hurricane recovery remains incomplete, a new natural disaster: a 6.4-magnitude earthquake followed by powerful aftershocks. (1/12)

The Wall Street Journal:Cancel Culture Comes To ScienceAn unhappy side effect of the digital age is cancel culture. Anyone with an attitude of moral superiority and a Twitter account can try to shut down an event where opinions he dislikes are likely to be spoken. For several years the National Association of Scholars has inveighed against this infantile form of protest, which undermines free expression of ideas and legitimate debate. Now the cancel caravan has arrived at our door. (Peter W. Wood, 1/12)

The Washington Post:The Crisis In Foster CareThe theory behind foster care is grounded in an assumption of stability placing children whose parents are absent, dead or deemed unfit with stable families where community, schools and peers are roughly familiar. The reality is increasingly the opposite. An acute shortage of foster parents has produced a cohort of vulnerable children, many with drug-addicted parents, who are sent away, sometimes out of state, to live in juvenile detention centers, shelters and group homes. (1/11)

The New York Times:Trumps Weakening Of Environmental Rules Would Leave The Public In The DarkFifty years ago this month, President Richard Nixon signed one of the most effective laws ever written to protect the environment and strengthen democracy by ensuring that citizens would have a say over projects like highways and pipelines that directly affect their well-being. Now President Trump is trying to cripple it. (Sharon Buccino, 1/10)

Louisville (Ky.) Courier Journal:We Must Increase Access To Mental Health Care. Too Many People Are DyingWhen facing the homicide crisis in the U.S., nearly all of us, citizens and politicians alike, jump to the same questions: What industry is at fault? Who needs tighter regulations? Nobody is asking this about our nations mental health. Our healthcare system today clearly is not meeting the needs of Americans suffering from mental illness. Health insurance companies follow vague and unenforceable federal and state regulations that leave enrollees without access to timely mental health care. (Caitlin Liford, 1/10)

Stat:Welcome To The Bioengineering Culture ClashBioengineering, once viewed primarily as an academic discipline, is growing up. Our ability to engineer biology is on the verge of changing the landscape of health and health care. Tools and treatments that are engineered, not discovered CAR-T therapies for cancer, CRISPR for gene editing, stem cell therapies, and more are now making their way not just into new startups but into established industry. Just look at the first-generation CAR-T companies that have been acquired by major biopharma companies, like Bristol-Myers Squibb/Celgene acquiring Juno or Gilead acquiring Kite. (Vijay Pande, 1/10)

The New York Times:Everyone Knows Memory Fails As You Age. But Everyone Is Wrong.Im 62 years old as I write this. Like many of my friends, I forget names that I used to be able to conjure up effortlessly. When packing my suitcase for a trip, I walk to the hall closet and by the time I get there, I dont remember what I came for. And yet my long-term memories are fully intact. I remember the names of my third-grade classmates, the first record album I bought, my wedding day. (Daniel J. Levitin, 1/10)

The Washington Post:A Psychiatrist Feels Guilt For Making A Homeless Man Leave The ER.Tonight was yet another night on call in our emergency room a chilly winter night on which I did a cruel deed: I discharged a homeless man back out into the cold. This is a routine event in the life of psychiatry residents like myself. Normally, no one would bat an eye. It shouldnt have mattered to me, either except that the previous night Id had to walk home from the hospital parking garage in decidedly adverse weather. (Aarya Krishnan Rajalakshmi, 1/12)

The Washington Post:Prince Georges Countys Mental Health Programs Dont Work. When Will Someone Listen?Its Dec. 29, 1 p.m., and Im at a hospital in Prince Georges County. The emergency room is packed with people with varying degrees of illnesses. Many have severe colds; others have flu symptoms. Some have broken ribs or fractures and cuts and bruises from domestic violence (and broken hearts). Sadly, some have come here to die, their families clinging to the hope that this talented yet overwhelmed staff can whip up a miracle. (Sharon K. Vollin, 1/10)

See the original post:
Viewpoints: Medicaid Expansion Reveals How Liberal Policies Make For Good Politics; Hey, Congress, What's The Hold Up With Surprise Medical Bills? -...